

# Building an Enhanced Analytical Toolbox for In-vivo Predictive Dissolution



Justin Pennington, Sanjay Patel, Jesse Kuiper, Amanda Mann, Andre Hermans  
PSCS-Analytical Sciences

# Outline

- Determination of Dissolution Mechanism
- 1x Bio-Relevant Dissolution
- Transfer Model for Weakly Basic APIs
- Future of Dissolution Methodology (Time Permitting)


# Outline

- Determination of Dissolution Mechanism
- 1x Bio-Relevant Dissolution
- Transfer Model for Weakly Basic APIs
- Future of Dissolution Methodology (Time Permitting)


# The Power of the Dissolution Test

Dissolution is the only product test that truly measures the effect of formulation and API physical properties on the rate of drug solubilization

Dissolution = disintegration + intrinsic dissolution



Disintegration





Solubilization






# Determination of Dissolution Mechanisms

- The determination of dissolution mechanism is mainly accomplished through visual observations.
- **Erosion Based:**
  - An observable “dry core” throughout the dissolution experiment.
  - May swell to some degree and granules may flake off
  - Measured Dissolution rate is relatively unaffected by granule properties
- **Granule Based:**
  - Rapid release of granules into the bulk solution
  - Granules will typically be large and will decrease in size over time
  - Tend to disintegrate rapidly and are highly affect by changes to granulation properties




# Dissolution Mechanism Summary

- The extent and location of dissolution of a pharmaceutical product is critical to ensure proper drug delivery to the patient and can greatly affect the observed pharmacokinetics for a drug candidate.
- While there are many factors at play to consider when evaluating dissolution, the general manner in which a dosage form dissolves can be generalized in the following matter.



**Note: Any factors (k) can be either rate limiting or potentially negligible.**

# Bioavailability Depends on Dissolution



- Dissolution is the best surrogate for bio-performance if IVIVC can be established.
- It enables selection/ rank ordering of formulation candidates in early development without the need to perform actual in vivo (animal or human) studies significantly accelerating development

# Outline

- Determination of Dissolution Mechanism
- **1x Bio-Relevant Dissolution**
- Transfer Model for Weakly Basic APIs
- Future of Dissolution Methodology (Time Permitting)

# Selection of Dissolution Conditions

**Biorelevant dissolution can be conducted under different sink conditions depending on the purpose of the study.**

## Dose Relevant

- Biorelevant dissolution may be conducted at dose relevant concentration which often exceeds the solubility limit of the most stable API phase in that medium.
- This is used to assess the behavior of a metastable API phase under supersaturated condition and the formulation impact on the kinetics of supersaturation


## 1x Solubility Limit

- **Standard Biorelevant test**
- Intended to probe the response of drug dissolution rate to API particle size distribution, wettability and dispersibility.
- May be conducted on all parts of the drug product from API and dispersion/extrudate through granules and tablets


# Dissolution at 1X versus Dose Relevant Concentrations

- 1X Solubility Approach Allows Quantitative Comparisons Across Formulation Types

**Calculated Dissolution at 1X - 5 ug/mL Drug Solubility, Varying PSD**



**Calculated Dissolution at Dose Relevant (40X) - 5 ug/mL Drug Solubility, Varying PSD**



# Practically, What Working at “1X” Means



- Using the 5  $\mu\text{g}/\text{mL}$  solubility in FaSSIF example, and the 100 mg dose


**← That's a lot of FaSSIF!**

- To work at “1X” with a complete 100 mg tablet then would require a 20,000 mL volume
- We work with granules (example here, 1/40<sup>th</sup> weight of a tablet in 500 mL faSSIF) or portions of tablets – or pre-disintegrated in SGF



# 1X Dissolution is Readily Modeled

If API is dispersed properly and that PSD put into the disso calculation –calc/experiment agree well



APIs pre-dispersed prior to putting in FaSSIF - drug added at 1 mg/ml



# This Approach Allows Quantitative Comparisons Across Formulation Types


Formulation Attribute	1x Dissolution Response
API Dispersion in dose	Formulations that do this better will have faster rates of dissolution than those that do this poorly
Granulation of API	Granulation can help with dispersion of particles in dissolution – also over granulation can add additional dissolution rate slowing (increase in $\rho$ term (particle density))
Addition of Surfactants	Helping wet the particles may improve dissolution rate



## This Approach Allows Quantitative Comparisons Across Formulation Types

**Understanding the dissolution rate of well dispersed API particles is the first step in evaluating dissolution performance – as a very well dispersed formulation with very fast granule dissolution will approach dispersed API dissolution rate.**

# Representative 1X Data Comparing Formulation Components




# Outline


- Determination of Dissolution Mechanism
- 1x Bio-Relevant Dissolution
- **Transfer Model for Weakly Basic APIs**
- Future of Dissolution Methodology (Time Permitting)


# Two-Stage Dissolution

During the typical two-stage dissolution, 1X addition of FaSSIF creates sudden pH change for the 2nd stage. This may be especially problematic for weak bases, which may undergo precipitation in the 2nd stage.




# Multicompartment Transfer Model to Predict Dissolution/Precipitation of Weakly Basic Drug





# Case Study: Ketoconazole



- Ketoconazole: Weak dibasic antifungal agent
- pKa: 2.94, 6.51
- BCS II
- Permeability:  
Caco-2  $P_{eff}=53 \times 10^{-6}$  cm/sec
- Solubility:
  - Virtually insoluble at pH 5 or higher
  - Detailed solubility profile (right)
- Administration:
  - Exposure was well known as being affected by elevated stomach pH
  - Recommended to codose w/acidic cola drink



pH	Solubility (mg/mL)
1.6 (FaSSGF)	9
3 (buffer)	1.8
3.5 (buffer)	0.7
4.5 (buffer)	0.25
5 (buffer)	0.1
6.5 (buffer)	0.007
SGF	6
FaSSIF	0.02537





# Ketoconazole Tablets: Transfer vs Two-Stage



- Some precipitation observed in the transfer model; significant precipitation in two-stage dissolution
- A **small amount of precipitation** was observed in fasted adult study (Psachoulias D, et al. *Pharm Res.* 2011;28(12):3145-3158. doi: 10.1007/s11095-011-0506-6)

# Case Study: Dipyridamole

- Inhibits thrombus formation (antiplatelet)
- Free base with pKa of 6.4
- BCS Class II
- Permeability: Estimated human Peff 1.5 (cm/sec x 10<sup>-4</sup>)
- Tablets: 25 mg, 50 mg, 75 mg
- Recommended dose: 75-100 mg 4 times daily
- **Significantly decreased exposure with famotidine-treated healthy elderly patients**
- **The absolute bioavailability is 27 +/- 5.5% (range 11% – 44%)**




Molecular Weight: 504.6, pKa = 6.4

pH	Solubility (mg/mL)
3.5	2.2
4.2	0.5
5	0.0054
6	0.0010
7	0.0005
7.8	0.0006
SGF	8
FaSSIF	0.01148

Terhaag B, et al. *Int J Clin Pharmacol Ther Toxicol.* 1986;24(6):298-302.  
 Glomme A, et al. *J Pharm Sci.* 2005;94(1):1-16.

# Dipyridamole Tablets: Transfer vs Two-Stage



- Both models indicate dipyridamole does not undergo rapid precipitation
- Absorption modeling studies also indicate a prolonged in vivo precipitation
- Dipyridamole precipitation is concentration dependent (Box K, et al. Approaches for measuring intestinal precipitation rates of oral drugs [abstract])



# Transfer Model Summary


- A multicompartment transfer system was established to investigate the in vivo behavior of weak basic compounds
- Preliminary data showed promising results to support transfer model as an alternative way to estimate in vivo precipitation in intestinal compartment for weak basic compounds
- Opportunities:
  - In silico model – Develop full mathematical model to describe simultaneous transfer/precipitation process
  - Nanoparticle formers/enabling formulation

# Outline

- Determination of Dissolution Mechanism
- 1x Bio-Relevant Dissolution
- Transfer Model for Weakly Basic APIs
- Future of Dissolution Methodology (Time Permitting)


# Atomic Force Microscopy

Atomic force microscopy (AFM) has been utilized to map topographical features, mechanical, electrical, and magnetic properties for nanoparticles, films, and biological materials with sub-nanometer resolution.




Single DNA Strand

<https://www.asylumresearch.com/Gallery/Cypher/Cypher34.shtml>



CTAB on Defect (graphite)

<https://www.asylumresearch.com/Gallery/Materials/SelfAssem/Self5.shtml>




Graphite (5nm x 5 nm) (STM)

<https://www.asylumresearch.com/Gallery/Cypher/Cypher1.shtml>



# Previous AFM Dissolution Experiments

AFM has been utilized to monitor the dissolution of acetaminophen crystals. Due to the challenge of collecting AFM images in liquids, these samples are exposed to the dissolution medium, dried, and then imaged.




Correlate AFM images to the intrinsic dissolution rate and changes in etching patterns to interaction between the polymer and acetaminophen.

Wen, H., Morris, K.R. & Park, K. Pharm Res (2008) 25: 349.

# Asylum AFM

Detection

Drives the  
cantilever




## Cypher ES blueDrive (Asylum Research)

Typically, piezoacoustic excitation is used to drive the cantilever oscillation. blueDrive excites the cantilever photothermally.






# Compound A Phosphate Buffer



Dissolution is slowed down by dissolving Compound A into the solution prior to addition to the AFM.


Phosphate buffer (pH 6.5)

# Compound A Phosphate Buffer



The surface appears to form pits on the surface  
Certain surface features are maintained throughout the experiment  
The etching starts near a defect and moves across the surface

# Compound A FaSSIF






Dissolution is slowed down by dissolving Compound A into the solution prior to addition to the AFM.

FaSSIF: Phosphate buffer + lecithin + sodium taurocholate (pH 6.5)






# Compound A FaSSIF



The surface has features that are <math>< 5\text{ nm}</math>  
Dissolution occurs in patches initially  
The final surface is very flat (1400pm)  
Dissolution is very different than that observed in phosphate



# Challenges

- Not all crystals are appropriate for AFM
- In order to track the surface, the solution must have the API added to slow down the dissolution → not as relevant to a dissolution experiment
- No chemical identification of sample
- Quantification is difficult outside of topography/phase
- More replicates needed, different facets show some differences in dissolution




# AFM Summary

- It is possible to monitor the dissolution of Compound A in *situ* in biologically relevant media (FaSSIF) via liquid AFM imaging
- The components in the media affect how the surface dissolves
- Interpretation is a challenge, but it can compliment traditional dissolution and characterization techniques



HPMCAS/Phosphate Buffer



# Conclusions

- It is vital to understand and determine the fundamental dissolution mechanism early in development to guide formulation and dissolution method development
- 1x Bio-relevant Dissolution provides a straightforward approach to formulation optimization through the “yardstick” approach
- Transfer Models provide an option to gain insight into more predictive dissolution rates for weakly basic compounds
- Future dissolution methodology such as AFM may provide a mechanism to understand dissolution at the nano-scale.



# Acknowledgements

- 1x: Paul Harmon, Jesse Kuiper, Mike Socki, and Adam Socia
- Transfer Studies: Sanjay Patel, Wei Zhu and Binfeng Xia
- AFM: Amanda Mann, Matt Lamm, Andre Hermans
- PSCS-Analytical Sciences

